Last checked at 2 Oct 2020 07:00
Synairgen plc
('Synairgen' or the 'Company')
Appointment of Joint Broker
Southampton, UK - 2 October 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, is pleased to announce the appointment of Numis Securities Limited as Joint Broker to the Company with immediate effect. finnCap remains Nominated Adviser and Joint Broker to the Company.
-Ends
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap (Nominated Advisor & Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media & Investor Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of
Southampton Professors Stephen Holgate, Donna Davies, and Ratko Djukanovic. The
business, focused primarily on lung viral defence in asthma, COPD, and COVID-19, uses its
differentiating human biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory disease. Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen, please see
https://www.synairgen.com